Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Doctors and the DEA Free full text
Top Ten Searches
parkinson's neuritis neuralgia myasthenia gravis lactic acidosis ataxia seizure tinnitus migraine hypotoniaYour Article Summary
See Latest ArticlesCSF oligoclonal band patterns reveal disease heterogeneity in multiple sclerosis
Journal of Neuroimmunology, 06/23/09
Villar LM et al. - The authors studied oligoclonal bands in 424 MS patients. Most primary progressive (PPMS) patients showed serum OCGB with additional bands in CSF. Conversely, most RRMS and secondary progressive (SPMS) patients showed OCGB exclusively in CSF. Moreover, no PPMS patient presented LS-OCMB, while 31% of RRMS and 60% of SPMS groups showed these antibodies. This suggests heterogeneous autoimmune mechanisms in MS.
Luisa M. Villar, 06/24/09
| These findings contribute to identificate of the different autoimmune responses occurring in relapsing-remitting and primary progressive MS. Their complete understanding will enable more specific treatment approaches in this disease. |
Today in Basic Science/Genetics...keeping you current
Receive free subspecialty "5-minute updates" via email
Urate as a Predictor of the Rate of Clinical Decline in Parkinson Disease
Archives of Neurology, 10/14/09
Changes in Hippocampal Metabolites After Effective Treatment for Fibromyalgia: A Case Study
The Clinical Journal of Pain, 10/20/09
Association of vitamin D deficiency with cognitive impairment in older women. Cross-sectional study
Neurology, 10/02/09
Today in Demyelinating Disorders...keeping you current
Receive free subspecialty "5-minute updates" via email
Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial : The Lancet
The Lancet - Early Online Publication, 10/08/09
Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial
The Lancet Neurology, 10/16/09
Sponsor
Article Search
Sponsor